Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of r18-7aa polypeptide modified by octadecylation and its derivative polypeptide

A technology of octadecyl and polypeptide, which is applied in the field of preparation of antithrombotic drugs, can solve problems such as increased bleeding risk, neutropenia, and weakened drug efficacy, and achieve the effect of inhibiting platelet aggregation

Active Publication Date: 2021-10-19
KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI
View PDF19 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the clinically used drugs for the prevention and treatment of thrombotic diseases mainly include anticoagulant drugs, thrombolytic drugs and antiplatelet aggregation drugs, but common antithrombotic drugs such as aspirin and clopidogrel often produce weakened drug effects, gastrointestinal Side effects such as irritation, neutropenia, increased risk of bleeding

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of r18-7aa polypeptide modified by octadecylation and its derivative polypeptide
  • Application of r18-7aa polypeptide modified by octadecylation and its derivative polypeptide
  • Application of r18-7aa polypeptide modified by octadecylation and its derivative polypeptide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0071] platelet aggregation inhibition test

[0072] Healthy human platelets were diluted with plasma to 2.5x10^8 / mL, 300 μL of diluted platelets were taken, and 10 μM, 30 μM and 100 μM of myrR18-7AA polypeptide were added respectively. After incubation at 37°C for 5 minutes, 30 μM of ADP and 2.25 μg / mL of Collagen induced platelet aggregation, and the aggregation curve within 5 minutes was drawn on a platelet aggregometer. Wash the platelets with bench-top solution, and finally dilute the platelets to 2.5x10^8 / mL with bench-top solution B, take 300 μL of washed platelets, add 0.21 μM, 0.63 μM, 1.85 μM and 5.56 μM myrR18 polypeptides, and incubate at 37 °C After 5 minutes, add 2.25 μg / mL collagen to induce platelet aggregation; add 1.85 μM, 5.55 μM, 16.67 μM, 50 μM and 150 μM myrR18 polypeptide respectively, and after incubation at 37°C for 5 minutes, add 0.18 U / mL collagen to induce platelet aggregation; Add 0.1 μM, 0.3 μM and 1 μM myrR18-7AA polypeptide respectively, incuba...

Embodiment 2

[0094] The co-localization of the octadecylated modified R18-7AA polypeptide with 14-3-3ζ;

[0095] Take the concentration as 1×10 4 / mL platelets were added with FITC-myrR18-7AA polypeptide (30 μM, amino acid sequence Myristoylated-SWLDLEA), and FITC-labeled myrR18-7AA disordered polypeptide (FITC-myrR18-7AAscr) was used as a negative control. After mixing, place in a 37°C incubator and incubate for 10 minutes. Add 1 mg / mL fibrinogen to the 12-well plate, air-dry for 2 hours, add the incubated platelets, add thrombin (0.12U / mL), mix well, place in an incubator, incubate at 37°C for 40 minutes, and remove the 12 wells platelet mixture in the plate, add PBS to remove the platelets that are not combined with fibrinogen and adhere to the wall, add 4% paraformaldehyde to fix, after 10min, remove the paraformaldehyde, wash with PBS three times, each After 5 minutes, use 0.3% Triton X-100 solution dissolved in PBS to rupture the membrane, remove after 10 minutes, add PBS to wash t...

Embodiment 3

[0098] The effect of myrR18-7AA polypeptide on the related proteins (c-Src protein, 14-3-3ζ, AKT protein) of integrin outside-in signaling pathway;

[0099] (1) Washed platelets were activated by collagen (1 μg / mL) using a platelet aggregator, and myrR18-7AA polypeptides of different concentrations (0 μM, 0.5 μM, 2.5 μM, 12.5 μM) were added to inhibit the activation of platelets. Platelet samples After obtaining, fully lyse;

[0100] (2) Take 20 μL of Dynabeads Protein A, absorb the magnetic beads with a magnetic stand, remove the solution, add 200 μL of PBS solution with 0.02% Tween-20, wash twice, add 2 μL of β3 protein antibody, and incubate at room temperature for 10 minutes.

[0101] (3) Adsorb the magnetic beads with a magnetic stand, remove the solution, centrifuge at 10,000 g for 5 min after the platelet sample is fully lysed, take the supernatant and add it to the magnetic beads, and incubate at room temperature for 10-30 min (adjust the incubation time according to t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of octadecylated modified R18-7AA polypeptide and its derivative polypeptide, and belongs to the technical field of preparation of antithrombotic drugs. The invention provides the application of the polypeptide in the preparation of drugs for antithrombotic and platelet aggregation inhibition. The polypeptide of the present invention can inhibit the aggregation of human platelets induced by collagen, thrombin and ADP by inhibiting the combination of 14‑3‑3ζ protein and integrin protein; it can significantly inhibit the extension of platelets, but it will not affect the interaction between platelets and The combination of fibrinogen can inhibit platelet aggregation by inhibiting the phosphorylation of related proteins in the integrin outside-in signaling pathway and affecting the interaction between 14‑3‑3ζ protein, c‑Src protein and integrin β3 protein; it can Significantly inhibit the aggregation of platelets, realize the preparation of anti-platelet aggregation and anti-thrombotic drugs without bleeding risk, and provide new ideas for the development of new and safe anti-thrombotic drugs in the future.

Description

technical field [0001] The invention relates to the technical field of preparation of antithrombotic drugs, in particular to the application of octadecylated modified R18-7AA polypeptides and derivative polypeptides thereof. Background technique [0002] A thrombus is a small clotted plaque formed by blood flow on the surface of a peeled or repaired vessel in the cardiovascular system. In the physiological process of coagulation, thrombus is the final product of the cascade reaction of the coagulation system, which is mainly composed of deposited platelets, insoluble fibrin, accumulated white blood cells and red blood cells. The formation of thrombus in the blood vessel will hinder the flow of blood flow, and even lead to the complete occlusion of the blood vessel. The thrombus peels off and detaches from the inner wall of the blood vessel and easily forms a migratory embolism. The resulting cardiovascular and cerebrovascular diseases include myocardial infarction, cerebral...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/08A61K38/10A61K47/54A61K38/16A61P7/02C07K14/00
CPCA61K38/16A61K47/54A61P7/02C07K14/00
Inventor 赖仞申传斌吕秋敏刘明李东升
Owner KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com